Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 1;8(10):e13821.
doi: 10.2196/13821.

Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial

Casey L Hall  1 , Cory E Fominaya  2 , Mulugeta Gebregziabher  1   3 , Sherry K Milfred-LaForest  4 , Kelsey M Rife  4 , David J Taber  1   2   5
Affiliations

Improving Transplant Medication Safety Through a Technology and Pharmacist Intervention (ISTEP): Protocol for a Cluster Randomized Controlled Trial

Casey L Hall et al. JMIR Res Protoc. .

Abstract

Background: Medication errors, adverse drug events, and nonadherence lead to increased health care utilization and increased risk of adverse clinical outcomes, including graft loss, in solid organ transplant recipients. Veterans living with organ transplants represent a population that is at substantial risk for medication safety events and fragmented care coordination issues. To improve medication safety and long-term clinical outcomes in veteran transplant patients, interventions should address interorganizational system failures and provider-level and patient-level factors.

Objective: This study aims to measure the clinical and economic effectiveness of a pharmacist-led, technology-enabled intervention, compared with usual care, in veteran organ transplant recipients.

Methods: This is a 24-month prospective, parallel-arm, cluster-randomized, controlled multicenter study. The pharmacist-led intervention uses an innovative dashboard system to improve medication safety and health outcomes, compared with usual posttransplant care. Pharmacists at 10 study sites will be consented into this study before undergoing randomization, and 5 sites will then be randomized to each study arm. Approximately, 1600 veteran transplant patients will be included in the assessment of the primary outcome across the 10 sites.

Results: This study is ongoing. Institutional review board approval was received in October 2018 and the study opened in March 2019. To date there are no findings from this study, as the delivery of the intervention is scheduled to occur over a 24-month period. The first results are expected to be submitted for publication in August 2021.

Conclusions: With this report, we describe the study design, methods, and outcome measures that will be used in this ongoing clinical trial. Successful completion of the Improving Transplant Medication Safety through a Technology and Pharmacist Intervention study will provide empirical evidence of the effectiveness of a feasible and scalable technology-enabled intervention on improving medication safety and costs.

Clinical trial: ClinicalTrials.gov NCT03860818; https://clinicaltrials.gov/ct2/show/NCT03860818.

International registered report identifier (irrid): PRR1-10.2196/13821.

Keywords: adherence; medication adherence; medication errors; transplant.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None declared.

Figures

None
Schematic representation of the process the pharmacist will use to identify, manage, and resolve potential medication safety issues.
See this image and copyright information in PMC

References

    1. Matas AJ, Smith JM, Skeans MA, Lamb KE, Gustafson SK, Samana CJ, Stewart DE, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 annual data report: kidney. Am J Transplant. 2013 Jan;13(Suppl 1):11–46. doi: 10.1111/ajt.12019. doi: 10.1111/ajt.12019. - DOI - PubMed
    1. Meier-Kriesche H, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378–83. doi: 10.1111/j.1600-6143.2004.00332.x. http://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pub... - DOI - PubMed
    1. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, Hidalgo LG, Famulski K, Matas A, Halloran PF. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012 Feb;12(2):388–99. doi: 10.1111/j.1600-6143.2011.03840.x. doi: 10.1111/j.1600-6143.2011.03840.x. - DOI - PubMed
    1. Dobbels F, de Geest S, van Cleemput J, Droogne W, Vanhaecke J. Effect of late medication non-compliance on outcome after heart transplantation: a 5-year follow-up. J Heart Lung Transplant. 2004 Nov;23(11):1245–51. doi: 10.1016/j.healun.2003.09.016. - DOI - PubMed
    1. Serper M, Patzer RE, Reese PP, Przytula K, Koval R, Ladner DP, Levitsky J, Abecassis MM, Wolf MS. Medication misuse, nonadherence, and clinical outcomes among liver transplant recipients. Liver Transpl. 2015 Jan;21(1):22–8. doi: 10.1002/lt.24023. doi: 10.1002/lt.24023. - DOI - PMC - PubMed

Associated data